Aripiprazole in Adolescents with Schizophrenia: Profile Report

Sanford, Mark; Keating, Gillian M.
April 2008
CNS Drugs;2008, Vol. 22 Issue 6, p529
Academic Journal
The article discusses the use of aripiprazole, an atypical antipsychotic drug, to treat adolescents who suffer from schizophrenia. Details about antipsychotic drug treatment for individuals with schizophrenia are provided. The features and properties of aripiprazole in the treatment of adolescent schizophrenia are also detailed and presented in a table.


Related Articles

  • Generics set to break Schizophrenia market.  // Pharmaceutical Technology Europe;Oct2006, Vol. 18 Issue 10, p12 

    The article reports that the global schizophrenia drug market has predicted to grow until 2010 according to the market analyst Datamonitor in the U.S. It will reach a value of $3.8 billion as genericized drugs will become cheaper which the efficacy of new branded offerings will not be higher...

  • Managing strep in a mono patient. Castle, Carla A. // Cortlandt Forum;2/25/95, Vol. 8 Issue 2, p53 

    Presents queries on the viability of treating adolescents with infectious mononucleosis and test positively for group A beta-hemolytic streptococci. Treatment of the streptococcal infection; Inadvisability of penicillin use.

  • Re: The Combined Use of Atypical Antipsychotics and Cognitive-Behavioural Therapy in Schizophrenia. Shelley, Anne-Marie; Opler, Lewis A.; Battaglia, Joseph; Lucey, Jeffrey // Canadian Journal of Psychiatry;Aug2003, Vol. 48 Issue 7, p496 

    Presents a letter to the editor regarding the combined use of atypical antipsychotics (AA) and cognitive-behavioral therapy (CBT) in schizophrenia. Overview of Dr. Duggal's patient findings; Comparison in symptom severity between patients receiving standard medication and those on therapy;...

  • Reply: The Combined Use of Atypical Antipsychotics and Cognitive-Behavioural Therapy in Schizophrenia. Duggal, Harpreet S. // Canadian Journal of Psychiatry;Aug2003, Vol. 48 Issue 7, p496 

    Presents the reply of the author to the letter on the combined use of atypical antipsychotics (AA) and cognitive-behavioral therapy (CBT) in schizophrenia. Agreement for more research on the interplay between AA and CBT; Potentiation of CBT by second-generation antipsychotics from reports of...

  • A controlled comparison of flupenthixol and amitriptyline in depressed outpatients. Young, J.P.R; Hughes, W.C.; Lader, M.H. // British Medical Journal;5/8/1976, Vol. 1 Issue 6018, p1116 

    Investigates the amitriptyline or flupenthixol treatment on depressed patients under double-blind procedures. Consideration on the treatment procedures; Developments on patients after treatments; Absence of distinct characteristics of drug effectivity.

  • From Eating Disorder to Schizophrenia. Taycan, Serap Erdogan; Demir, Suleyman; Celikel, Feryal Cam // Dusunen Adam: Journal of Psychiatry & Neurological Sciences;Jun2013, Vol. 26 Issue 2, p225 

    A letter to the editor about the case of a 16-year-old female patient with the comorbidity of eating disorders with psychosis.

  • Does combined neuroleptic-electroconvulsive therapy treatment increase the likelihood of creatine phosphokinase rise? Geizer, Maria; Ancill, R. J.; Geizer, M // Canadian Journal of Psychiatry;Feb1997, Vol. 42 Issue 1, p88 

    A letter to the editor is presented in response to the article "Does Electroconvulsive Therapy Exacerbate the Elevation of Creatinine Phosphokinase Caused by Neuroleptics," by M. Geizer and R. Ancill in the previous issue.

  • Atypical antipsychotics and glycemia: a case report. Waldman, Jeffrey C; Yaren, Stanley // Canadian Journal of Psychiatry;Sep2002, Vol. 47 Issue 7, p686 

    Examines the case illustrating atypical antipsychotics and glycemia. Investigation on the cases of glucose intolerability and diabetic ketoacidosis (DKA) associated with olanzapine; Difficulty of normalizing blood sugar after DKA; Introduction of clozapine to patients.

  • Is levomepromazine stable over time? Hardy, J.; O'Shea, A.; Gilbert, C.; Norris, R. // Palliative Medicine;Apr2011, Vol. 25 Issue 3, p284 

    Levomepromazine (methotrimeprazine) is an anti-psychotic used at low dose for the control of nausea and vomiting. When levomepromazine hydrochloride as Nozinan® is diluted with 0.9% sodium chloride at concentrations ranging from 0.13 to 6.25 mg/ml, and stored in polypropylene syringes, the...

  • Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary. Takács, P.; Czobor, P.; Fehér, L.; Gimesi-Országh, J.; Fadgyas-Freyler, P.; Bacskai, M.; Rakonczai, P.; Borsi, A.; Hegyi, R.; Németh, T.; Sermon, J.; Bitter, I. // PLoS ONE;6/13/2019, Vol. 14 Issue 6, p1 

    Background: Schizophrenia is a severe condition that affects approximately 1% of the population. Certain elements of antipsychotic treatment can only be examined in large population, thus the need for population-based real-world analyses has been increasing. Patients and methods: Hungarian...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics